Cushing's Syndrome

Endocrinology
8
Pipeline Programs
3
Companies
8
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 4 programs with unclassified modality

On Market (3)

Approved therapies currently available

Corcept Therapeutics
KORLYMApproved
mifepristone
Corcept Therapeutics
Progestin Antagonist [EPC]oral2012
U
MIFEPREXApproved
mifepristone
Unknown Company
oral2000
U
MIFEPRISTONEApproved
mifepristone
Unknown Company
Progestin Antagonist [EPC]oral2025

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
4 programs
1
2
1
mifepristonePhase 31 trial
mifepristonePhase 31 trial
CORT125134Phase 21 trial
Cushing's syndrome confirmationN/A1 trial
Active Trials
NCT00796783Terminated2
NCT02804750Completed35Est. Sep 2018
NCT00936741Completed30Est. Sep 2012
+1 more trials
Recordati
RecordatiFrance - Saint-Victor
2 programs
1
osilodrostatPhase 2Small Molecule1 trial
OsilodrostatN/ASmall Molecule1 trial
Active Trials
NCT05633953Completed103Est. Oct 2023
NCT03606408Completed127Est. Nov 2023
Novartis
NovartisBASEL, Switzerland
1 program
1
OsilodrostatPhase 2Small Molecule2 trials
Active Trials
NCT02399202Completed15Est. Mar 2016
NCT02468193Completed9Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Corcept Therapeuticsmifepristone
Corcept Therapeuticsmifepristone
Recordatiosilodrostat
Corcept TherapeuticsCORT125134
NovartisOsilodrostat
NovartisOsilodrostat
RecordatiOsilodrostat
Corcept TherapeuticsCushing's syndrome confirmation

Clinical Trials (8)

Total enrollment: 371 patients across 8 trials

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Start: Jul 2009Est. completion: Sep 201230 patients
Phase 3Completed

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Start: Dec 200750 patients
Phase 3Completed

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Start: Oct 2018Est. completion: Nov 2023127 patients
Phase 2Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Start: Jun 2016Est. completion: Sep 201835 patients
Phase 2Completed

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Start: Sep 2015Est. completion: Oct 20189 patients
Phase 2Completed

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Start: Nov 2015Est. completion: Mar 201615 patients
Phase 1Completed

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

Start: Jan 2023Est. completion: Oct 2023103 patients
N/ACompleted
NCT00796783Corcept TherapeuticsCushing's syndrome confirmation

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Start: Feb 20092 patients
N/ATerminated

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space